REPRISE
Tolvaptan Safety and Efficacy in Later-Stage ADPKD
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 1,370 patients with later-stage ADPKD, tolvaptan slowed eGFR decline compared with placebo.
N
1.370
Design
Double-blind RCT over 12 months
Endpunkt
Change in eGFR from baseline
Relevanz
3
Ergebnis−2.34 vs −3.61 mL/min/1.73m²/yr; difference 1.27 (95% CI 0.86–1.68; p<0.001).
Torres VE, et al. N Engl J Med. 2017;377(20):1930-1942. 10.1056/NEJMoa1710030
Diskussion & Kritik
Extended the tolvaptan indication to more advanced CKD stages of ADPKD.